NK9 Stock Overview
A biopharmaceutical company, develops drugs for the treatment of neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Neuren Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$8.20 |
| 52 Week High | AU$12.31 |
| 52 Week Low | AU$6.10 |
| Beta | 2.19 |
| 1 Month Change | 20.59% |
| 3 Month Change | 18.84% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| NK9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -12.8% | 1.5% | 1.9% |
| 1Y | n/a | -7.6% | 15.1% |
Return vs Industry: Insufficient data to determine how NK9 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NK9 performed against the German Market.
Price Volatility
| NK9 volatility | |
|---|---|
| NK9 Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NK9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NK9's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Jon Pilcher | www.neurenpharma.com |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.
Neuren Pharmaceuticals Limited Fundamentals Summary
| NK9 fundamental statistics | |
|---|---|
| Market cap | €1.10b |
| Earnings (TTM) | €70.32m |
| Revenue (TTM) | €115.91m |
15.7x
P/E Ratio9.5x
P/S RatioIs NK9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NK9 income statement (TTM) | |
|---|---|
| Revenue | AU$193.34m |
| Cost of Revenue | AU$32.90m |
| Gross Profit | AU$160.44m |
| Other Expenses | AU$43.15m |
| Earnings | AU$117.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 82.98% |
| Net Profit Margin | 60.67% |
| Debt/Equity Ratio | 0% |
How did NK9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 20:30 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Tara Speranza | Bell Potter |